Medicaid “Best Price” May Be Avenue To Challenge “Authorized” Generics

FDA's decision not to block "authorized" generic agreements may prompt interest in exploring Medicaid "best price" reporting requirements as another avenue for ending the practice

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet